Lv11
38 积分 2023-12-19 加入
A therapeutic algorithm guiding subsequent therapy selection after CDK4/6 inhibitors’ failure: a review of current and investigational treatment for HR+/Her2- breast cancer
2小时前
待确认
Lymph node dissection in small peripheral lung cancer: Supplemental analysis of JCOG0802/WJOG4607L
20小时前
已完结
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
12天前
已完结
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
1个月前
已完结
Towards targeting the breast cancer immune microenvironment
1个月前
已完结
Tackling Osimertinib Resistance in EGFR-Mutant Non–Small Cell Lung Cancer
3个月前
已完结
Response to First-Line Osimertinib Treatment in Non–Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations
6个月前
已关闭
Afatinib response in a lung adenocarcinoma with novel compound S720F+L861R mutation in EGFR
7个月前
已关闭
皖公网安备34019202002308
